Lurtotecan

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameLurtotecan
Drug Alias Name勒托替康lurtotecanumOSI-211 (Liposomal formulation)NX-211 (Liposomal formulation)GI-147211 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences IncAstellas Pharma IncOsi Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG